Business
SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS
- Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse racial and ethnic backgrounds - SALT LAKE CITY, Nov. 15,
About this update from Sera Prognostics, Inc.
[{"type":"text","content":"- Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse racial and ethnic backgrounds -\nSALT LAKE CITY, Nov. 15, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of results from a clinical utility and cost-effectiveness modeling study, ACCORDANT (Analyses aCross Congruent studies ReDucing Adverse pregNancy ouTcomes). The newly published study reports:\n\n \n \n \n \n \n \n\n \nCase management, which consists of increased outreach, education, and specialist care for women predicted to be at higher risk for delivering prematurely, was expected to decrease neonatal and maternal hospital length of stay by 19% (p=0.029) and 8.5% (p=0.001), respectively, compared with standard care.Case management for those at higher risk also was predicted to significantly reduce moderate-to-severe neonatal morbidity and mortality by 29% (p=0.025).Multimodal management, which combines case management with pharmacological treatment, was predicted to further improve outcomes and statistical significanceThe modeled clinical benefits and cost-effectiveness of the test-and-treat strategies were seen across diverse racial and ethnic backgrounds, with Black and Hispanic women strongly represented in the study.\"Results of this analysis point to the utility of the PreTRM® test-and-treat strategy in ameliorating the clinical and economic effects of preterm delivery, which impacts more than 10% of U.S. births each year,\" said Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics. \"Most importantly, the predicted benefits across underserved populations, among whom the prevalence of preterm birth is disproportionately increased, provide the opportunity to serve a broad and diverse population of women in the United States. We are excited to be in a position to help substantively address unacceptable healthcare disparities in pregnant populations that unfortunately bear the burdens of prematurity.\"\n\"By combining the PreTRM® Test, which detects far more women at risk of preterm birth than traditional clinical factors, with enhanced prenatal case management, real progress may be possible for this under-addres...